

(19) World Intellectual Property Organization
International Bureau



13
B

(43) International Publication Date
2 September 2004 (02.09.2004)

PCT

(10) International Publication Number
WO 2004/074224 A1

(51) International Patent Classification⁷: **C07C 13/615**,
A61P 37/00, 29/00, A61K 31/166

(21) International Application Number:
PCT/SE2004/000227

(22) International Filing Date: 19 February 2004 (19.02.2004)

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
0300480-1 21 February 2003 (21.02.2003) **SE**

(71) Applicant (for all designated States except US): **ASTRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE)**.

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CAFFREY, Moya [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough, Leicestershire LE11 5RH (GB).** **FORD, Rhonan [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough, Leicestershire LE11 5RH (GB).** **PIMM, Austen [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough, Leicestershire LE11 5RH (GB).**

(74) Agent: **GLOBAL INTELLECTUAL PROPERTY; AstraZeneca AB, S-151 85 Södertälje (SE).**

(81) Designated States (unless otherwise indicated, for every kind of national protection available): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)**

GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): **ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).**

Declaration under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)**

[Continued on next page]

(54) Title: **ADAMANTANE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM**



(I)

(57) **Abstract:** The invention provides compounds of formula (I) in which m, n, R¹₁, R²₂, R³₃, R⁴₄ and R⁵₅ have the meanings defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy.

WO 2004/074224 A1



Published:

— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Adamantane derivatives, processes for their preparation and pharmaceutical compositions containing them.


The present invention relates to adamantane derivatives, processes for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy.

The P2X₇ receptor (previously known as P2Z receptor), which is a ligand-gated ion channel, is present on a variety of cell types, largely those known to be involved in the inflammatory/immune process, specifically, macrophages, mast cells and lymphocytes (T and B). Activation of the P2X₇ receptor by extracellular nucleotides, in particular adenosine triphosphate, leads to the release of interleukin-1 β (IL-1 β) and giant cell formation (macrophages/microglial cells), degranulation (mast cells) and proliferation (T cells), apoptosis and L-selectin shedding (lymphocytes). P2X₇ receptors are also located on antigen-presenting cells (APC), keratinocytes, salivary acinar cells (parotid cells), hepatocytes and mesangial cells.

It would be desirable to make compounds effective as P2X₇ receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases, in the aetiologies of which the P2X₇ receptor may play a role.

20

In accordance with the present invention, there is therefore provided a compound of formula



wherein m represents 1, 2 or 3, preferably 1 or 2;

each R¹ independently represents a hydrogen or halogen (e.g. fluorine, chlorine, bromine

or iodine) atom, preferably a hydrogen atom;

one of R² and R³ represents halogen, nitro, amino, hydroxyl, or a group

5 selected from (i) C₁-C₆ alkyl optionally substituted by at least one halogen atom,

(ii) C₃-C₈ cycloalkyl, (iii) C₁-C₆ alkoxy optionally substituted by at least one halogen

atom, and (iv) C₃-C₈ cycloalkyloxy, and the other of R² and R³ represents a hydrogen or

halogen atom;

n represents 0, 1 or 2; and

10 R⁴ and R⁵ each independently represent a hydrogen atom or a C₁-C₆ alkyl group optionally substituted by at least one substituent selected from hydroxyl, halogen and C₁-C₆ alkoxy; or a pharmaceutically acceptable salt or solvate thereof.

In the context of the present specification, unless otherwise indicated, an alkyl substituent 15 or alkyl moiety in a substituent group may be linear or branched. Examples of alkyl groups/moieties containing up to 6 carbon atoms include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl and n-hexyl. Further, it should be appreciated that if R⁴ and/or R⁵ represents a C₁-C₆ alkyl group substituted by at least one substituent being a hydroxyl or C₁-C₆ alkoxy group, the hydroxyl or alkoxy substituent 20 will not be attached to the carbon atom which is adjacent to the nitrogen atom.

One of R² and R³ represents a halogen (e.g. fluorine, chlorine, bromine or iodine), nitro, 25 amino (-NH₂), hydroxyl, or a group selected from (i) C₁-C₆ alkyl, preferably C₁-C₄ alkyl, optionally substituted by at least one (e.g. one, two, three or four) halogen atom(s) as defined above, (ii) C₃-C₈ cycloalkyl (e.g. cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), (iii) C₁-C₆ alkoxy, preferably C₁-C₄ alkoxy, optionally substituted by at least one (e.g. one, two, three or four) halogen atom(s) as defined above, and (iv) C₃-C₈ cycloalkyloxy (e.g. cyclopropyloxy, cyclobutyloxy, cyclopentyloxy or cyclohexyloxy), and the other of R² and R³ represents a hydrogen or halogen atom as 30 defined above.

In one embodiment of the invention, one of R^2 and R^3 represents a halogen (such as a chlorine or bromine) atom and the other of R^2 and R^3 represents a hydrogen atom.


5 In an embodiment of the invention, m is 1.

In another embodiment of the invention, R^3 represents a hydrogen atom.

In another embodiment of the invention, n is 1.

10

In a further embodiment of the invention, n is 1 and the compound of formula (I) has the following stereochemistry:



15 R^4 and R^5 each independently represent a hydrogen atom or a C_1 - C_6 , for example, C_1 - C_4 or C_1 - C_3 , alkyl group which may be optionally substituted by at least one substituent (e.g. one, two, three or four substituents independently) selected from hydroxyl, halogen (e.g. fluorine, chlorine, bromine or iodine) and C_1 - C_6 , for example, C_1 - C_4 , alkoxy (e.g. methoxy, ethoxy, n-propoxy, n-butoxy, n-pentoxy and n-hexoxy).

20

In an embodiment of the invention, R^4 and R^5 each independently represent a hydrogen atom or a C_1 - C_6 alkyl group which may be optionally substituted by at least one, e.g. one or two, hydroxyl group(s).

In another embodiment of the invention, R⁴ and R⁵ each independently represent a hydrogen atom or a group selected from -CH₃, -C₂H₅, -CH(CH₃)₂, -CH₂OH, -(CH₂)₂OH, -(CH₂)₃OH, -CH(CH₃)CH₂OH, -CH₂CH(CH₃)OH, -CH₂CH(OH)CH₃, -CH₂CH(OH)CH₂OH, -CH₂C(CH₃)₂OH, -CH(isopropyl)CH₂OH, -CH(CH₂OH)₂, or -CH₂C(CH₃)₂CH₂OH.

In another embodiment of the invention, R⁴ and R⁵ each independently represent a group selected from -CH₃, -C₂H₅, -CH(CH₃)₂ and -(CH₂)₃OH.

10 In an embodiment of the invention, there is provided a subset of compounds of formula (I), pharmaceutically acceptable salts and solvates thereof, in which:

m represents 1;

each R¹ represents a hydrogen atom;

one of R² and R³ represents a halogen atom, and the other of R² and R³ represents a hydrogen atom;

n is 0, 1 or 2; and

R⁴ and R⁵ each independently represent a hydrogen atom or a group selected from -CH₃, -C₂H₅, -CH(CH₃)₂ and -(CH₂)₃OH.

20 In another embodiment of the invention, there is provided a further subset of compounds of formula (I), and pharmaceutically acceptable salts and solvates thereof, in which:

m represents 1;

each R¹ represents a hydrogen atom;

one of R² and R³ represents a halogen atom, and the other of R² and R³ represents a

25 hydrogen atom;

n is 0, 1 or 2; and

one of R⁴ and R⁵ represents a hydrogen atom or -CH₃ and the other of R⁴ and R⁵ represents a group selected from -CH₃, -C₂H₅, -CH(CH₃)₂ and -(CH₂)₃OH.

30 Examples of compounds of the invention include:

2-Chloro-5-[(3S)-3-hydroxy-4-(methylamino)butyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide,

2-Chloro-5-[(3S)-3-hydroxy-4-(ethylamino)butyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide,

5 2-Chloro-5-[(3S)-3-hydroxy-4-(1-methylethylamino)butyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide,

2-Chloro-5-[(3R)-3-hydroxy-4-(methylamino)butyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide,

2-Chloro-5-[(2R)-3-(ethylamino)-2-hydroxypropyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-10 benzamide hydrochloride,

2-Chloro-5-[(2R)-2-hydroxy-3-[(1-methylethyl)amino]propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide hydrochloride,

2-Chloro-5-[(2R)-2-hydroxy-3-[(3-hydroxypropyl)amino]propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide hydrochloride,

15 2-Chloro-5-[(2R)-3-(dimethylamino)-2-hydroxypropyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide hydrochloride,

2-Chloro-5-[(1S)-1-hydroxy-2-(methylamino)ethyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide hydrochloride,

20 2-Chloro-5-[(1R)-1-hydroxy-2-(methylamino)ethyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide hydrochloride,

2-Chloro-5-[(1R)-2-(ethylamino)-1-hydroxyethyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide,

2-Chloro-5-[(1R)-1-hydroxy-2-[(3-hydroxypropyl)amino]ethyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide,

25 2-Chloro-5-[(2S)-2-hydroxy-3-(methylamino)propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide hydrochloride,


2-Chloro-5-[(2S)-3-(ethylamino)-2-hydroxypropyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide hydrochloride,

30 2-Chloro-5-[(2R)-2-hydroxy-3-(methylamino)propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide benzoic acid salt,

and all pharmaceutically acceptable salts and solvates of any one thereof.

The present invention further provides a process for the preparation of a compound of formula (I) as defined above, or a pharmaceutically acceptable salt or solvate thereof,
5 which comprises:

(i) when n is 0, reacting a compound of formula




(II)

10

wherein m , R^1 , R^2 and R^3 are as defined in formula (I), with a compound of formula (III), HNR^4R^5 , wherein R^4 and R^5 are as defined in formula (I); or

(ii) when n is 1, reacting a compound of formula

15




(IV)

wherein m , R^1 , R^2 and R^3 are as defined in formula (I), with a compound of formula (III) as defined in (i) above; or

(iii) when n is 2, reacting a compound of formula


5



wherein L^1 is a leaving group (e.g. halogen, nitrobenzenesulfonyl, methanesulfonyl or an alternative leaving group for nucleophilic displacement reactions) and m , R^1 , R^2 and R^3 are as defined in formula (I), with a compound of formula (III) as defined in (i) above; or

10

(iv) when n is 1, reacting a compound of formula




15 wherein L^2 is a leaving group (e.g. halogen, nitrobenzenesulfonyl, methanesulfonyl or an alternative leaving group for nucleophilic displacement reactions) and m , R^1 , R^2 and R^3 are as defined in formula (I), with a compound of formula (III) as defined in (i) above;


and optionally after (i), (ii) (iii) or (iv) carrying out one or more of the following:

- converting the compound obtained to a further compound of formula (I)
- forming a pharmaceutically acceptable salt or solvate of the compound.

5 In process (i), the compound of formula (II) may be conveniently synthesised by reacting a compound of formula




wherein L^3 represents a leaving group (e.g. halogen, phosphate, trifluoromethane sulphonate or an alternative leaving group for metal catalysed coupling reactions) and m ,
10 R^1 , R^2 and R^3 are as defined in formula (I), with a compound of formula





wherein L^4 represents a leaving group (e.g. trialkyltin, boronic acid or an alternative leaving group for metal catalysed coupling reactions) under metal catalysed coupling conditions such as *tetrakis(triphenylphosphine)palladium(0)*.

15 The subsequent oxidation reaction may be performed with a reagent such as *m*-chloroperbenzoic acid in a suitable solvent such as dichloromethane.

Compounds of formula (II) may also be prepared by reacting a compound of formula




wherein m , R^1 , R^2 and R^3 are as defined in formula (I), with a compound of formula (XIII) or (XIV) suitably deprotonated by a base such as sodium hydride,




5

Reaction of the resultant epoxide may be performed by addition of the required amine of formula (III) at room temperature or at elevated temperature. An example of a compound of formula (XIII) is trimethylsulfonium iodide.

10 In process (ii), the compound of formula (IV) may be conveniently synthesised by reacting a compound of formula




wherein L^5 represents a leaving group (e.g. halogen, phosphate, trifluoromethane sulphonate or an alternative leaving group for metal catalysed coupling reactions) and m , R^1 , R^2 and R^3 are as defined in formula (I), with a compound of formula



wherein L^6 represents a leaving group (e.g. trialkyltin, trialkylsilane, boronate, boronic acid or an alternative leaving group for metal catalysed coupling reactions) under metal catalysed coupling conditions such as dichlorobis(triphenylphosphine)palladium(II). The subsequent oxidation reaction may be performed with a reagent such as *m*-chloroperbenzoic acid or a combination of pyrazole, methyltrioxorhenium(VII) and hydrogen peroxide in a suitable solvent such as dichloromethane.


Compounds of formula (IV) may also be prepared by reacting a compound of formula




wherein m , R^1 , R^2 and R^3 are as defined in formula (I), with a compound of formula (XIII) or (XIV) as defined above suitably deprotonated by a base such as sodium hydride.

Reaction of the resultant epoxide may be performed by addition of the required amine of formula (III) at room temperature or at elevated temperature.

In process (iii), the compound of formula (V) may be conveniently synthesised by reacting a compound of formula




wherein L^7 represents a leaving group (e.g. halogen, phosphate, trifluoromethane sulphonate or an alternative leaving group for metal catalysed coupling reactions) and m , R^1 , R^2 and R^3 are as defined in formula (I), with a compound of formula




5 wherein P^1 and P^2 each independently represent a protecting group, in the presence of tetrakis(triphenylphosphine)palladium(0), followed by removal of the protecting groups with a reagent such as hydrochloric acid and reaction with a reagent such as methanesulphonyl chloride. Protecting groups P^1 and P^2 may be selected from any of the 10 wide range of hydroxyl protecting groups known in the art.

The compound of formula (V) may be reacted with the amine of formula (III) at room temperature or at elevated temperature.

15 In process (iv), the compound of formula (VI) may be conveniently synthesised by reacting a compound of formula



wherein L^8 represents a leaving group (e.g. halogen, phosphate, trifluoromethane sulphonate or an alternative leaving group for metal catalysed coupling reactions) and m , R^1 , R^2 and R^3 are as defined in formula (I) (suitably metallated with a reagent such as 5 butyllithium or *isopropylmagnesium chloride* followed by addition of copper(I) bromide dimethylsulphide complex), with a compound of formula



10 wherein L^9 is a leaving group (e.g. halogen, nitrobenzenesulfonyl, methanesulfonyl or an alternative leaving group for nucleophilic displacement reactions), followed by reaction with a reagent such as methanesulphonyl chloride.

The compound of formula (VI) may be reacted with the amine of formula (III) at room temperature or at elevated temperature.

15 Compounds of formula (I) can be converted into further compounds of formula (I) using standard procedures. For example, compounds of formula (I) in which one of R^2 and R^3 represents a halogen atom may be converted to a corresponding compound of formula (I) in which one of R^2 and R^3 represents a C_1 - C_6 alkyl group by reaction with an alkyl 20 Grignard reagent (e.g. methyl magnesium bromide) in the presence of a catalyst such as [1,3-bis(diphenylphosphino)propane]dichloronickel (II) in a solvent such as tetrahydrofuran.

Compounds of formula (X), (XII), (XV), (XVII), (XVIII) referred to above may be prepared by known chemistry, for example by methods according or analogous to those described in WO 99/29661 and WO 00/61569.

5 It will be appreciated by those skilled in the art that in the processes of the present invention certain functional groups such as hydroxyl or amino groups in the starting reagents or intermediate compounds may need to be protected by protecting groups. Thus, the preparation of the compounds of formula (I) may involve, at various stages, the addition and removal of one or more protecting groups.

10

The protection and deprotection of functional groups is described in 'Protective Groups in Organic Chemistry', edited by J.W.F. McOmie, Plenum Press (1973) and 'Protective Groups in Organic Synthesis', 2nd edition, T.W. Greene and P.G.M. Wuts, Wiley-Interscience (1991).

15

The compounds of formula (I) above may be converted to a pharmaceutically acceptable salt or solvate thereof, preferably an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, oxalate, methanesulphonate or *p*-toluenesulphonate, or an alkali metal salt such as a sodium or potassium salt.

20 Certain compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses all geometric and optical isomers of the compounds of formula (I) and mixtures thereof including racemates. Tautomers and mixtures thereof also form an aspect of the present invention. Enantiomerically pure forms are particularly desired.

25 The compounds of the present invention are advantageous in that they possess pharmacological activity. They are therefore indicated as pharmaceuticals for use in the treatment of rheumatoid arthritis, osteoarthritis, psoriasis, allergic dermatitis, asthma,

chronic obstructive pulmonary disease (COPD), hyperresponsiveness of the airway, septic shock, glomerulonephritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, atherosclerosis, growth and metastases of malignant cells, myoblastic leukaemia, diabetes, Alzheimer's disease, meningitis, osteoporosis, burn injury, ischaemic heart disease, stroke, 5 varicose veins, sarcoidosis, rhinitis, acute and chronic pain, multiple sclerosis, myeloma, bone loss associated with malignancy and inflammatory and neurodegenerative diseases of the eye such as scleritis, episcleritis, uveitis, Sjogrens syndrome-keratoconjunctivitis, sclerokeratitis, optic neuritis, diabetic retinopathy, retinitis pigmentosa, antimarial - induced retinopathy.

10

Accordingly, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as hereinbefore defined for use in therapy.

15 In another aspect, the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as hereinbefore defined in the manufacture of a medicament for use in therapy.

20 In the context of the present specification, the term "therapy" also includes "prophylaxis" unless there are specific indications to the contrary. The terms "therapeutic" and "therapeutically" should be construed accordingly.

25 The invention further provides a method of effecting immunosuppression (e.g. in the treatment of rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, atherosclerosis or psoriasis) which comprises administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as hereinbefore defined to a patient.

30 The invention also provides a method of treating an obstructive airways disease (e.g. asthma or COPD) which comprises administering to a patient a therapeutically effective

amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as hereinbefore defined to a patient.

For the above-mentioned therapeutic uses the dosage administered will, of course, vary 5 with the compound employed, the mode of administration, the treatment desired and the disorder indicated. The daily dosage of the compound of formula (I)/salt/solvate (active ingredient) may be in the range from 0.001 mg/kg to 30 mg/kg.

The compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof 10 may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the formula (I) compound/salt/solvate (active ingredient) is in association with a pharmaceutically acceptable adjuvant, diluent or carrier. Depending on the mode of administration, the pharmaceutical composition will preferably 15 comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.10 to 70 %w, of active ingredient, and, from 1 to 99.95 %w, more preferably from 30 to 99.90 %w, of a pharmaceutically acceptable adjuvant, diluent or carrier, all percentages by weight being based on total composition.

Thus, the present invention also provides a pharmaceutical composition comprising a 20 compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as hereinbefore defined in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

The invention further provides a process for the preparation of a pharmaceutical 25 composition of the invention which comprises mixing a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as hereinbefore defined with a pharmaceutically acceptable adjuvant, diluent or carrier.

The pharmaceutical composition of the invention may be administered topically (e.g. to the 30 lung and/or airways or to the skin) in the form of solutions, suspensions, heptafluoroalkane

aerosols and dry powder formulations; or systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules, or by parenteral administration in the form of solutions or suspensions, or by subcutaneous administration or by rectal administration in the form of suppositories or transdermally.

5

The invention further relates to combination therapies for the treatment of any one of rheumatoid arthritis, osteoarthritis, osteoporosis, psoriasis, inflammatory bowel diseases, COPD, asthma, allergic rhinitis or cancer or the neurodegenerative diseases such as multiple sclerosis, Alzheimer's disease or stroke.

10

For the treatment of rheumatoid arthritis, the compounds of the invention may be combined with "biological agents" such as TNF- α inhibitors such as anti-TNF monoclonal antibodies (such as Remicade, CDP-870 and Humira) and TNF receptor immunoglobulin molecules (such as Enbrel^{reg.}). IL-1 receptor antagonist (such as Anakinra) and IL-1 trap, IL-18 receptor, anti-IL-6 Ab, anti-CD20 Ab, anti-IL-15 Ab and CTLA4Ig.

Suitable agents to be used in combination include standard non-steroidal anti-inflammatory agents (hereinafter NSAID's) such as piroxicam, diclofenac, propionic acids such as naproxen, flubiprofen, fenoprofen, ketoprofen and ibuprofen, fenamates such as mefenamic acid, indomethacin, sulindac, apazone, pyrazolones such as phenylbutazone, salicylates such as aspirin. The COX-2 inhibitors (such as meloxicam, celecoxib, rofecoxib, valdecoxib and etoricoxib) and the cyclooxygenase inhibiting nitric oxide donors (CINOD's) and the "disease modifying agents" (DMARDs) such as methotrexate, sulphasalazine, cyclosporine A, lefunomide; ciclesonide; hydroxychloroquine, d-penicillamine, auranofin or parenteral or oral gold.

The present invention still further relates to the combination of a compound of the invention together with a leukotriene biosynthesis inhibitor, 5-lipoxygenase (5-LO) inhibitor or 5-lipoxygenase activating protein (FLAP) antagonist selected from the group consisting of zileuton; ABT-761; fenleuton; tepoxalin; Abbott-79175; Abbott-85761; N-(5-

substituted)-thiophene-2-alkylsulfonamides; 2,6-di-tert-butylphenol hydrazones; methoxytetrahydropyrans such as Zeneca ZD-2138; the compound SB-210661; pyridinyl-substituted 2n cyanonaphthalene compounds such as L-739,010; 2-cyanoquinoline compounds such as L-746,530; indole and quinoline compounds such as MK-591, MK-886, and BAY x 1005.

5 The present invention still further relates to the combination of a compound of the invention together with a receptor antagonists for leukotrienes LTB₄, LTC₄, LTD₄, and LTE₄ selected from the group consisting of the phenothiazin-3-ones such as L-651,392; amidino compounds such as CGS-25019c; benzoxalamines such as ontazolast; benzenecarboximidamides such as BIIL 284/260; and compounds such as zafirlukast, ablukast, montelukast, pranlukast, verlukast (MK-679), RG-12525, Ro-245913, iralukast (CGP 45715A), and BAY x 7195.

10 15 The present invention still further relates to the combination of a compound of the invention together with a PDE4 inhibitor including inhibitors of the isoform PDE4D.

20 The present invention still further relates to the combination of a compound of the invention together with a antihistaminic H₁ receptor antagonists including cetirizine, loratadine, desloratadine, fexofenadine, astemizole, azelastine, and chlorpheniramine.

25 The present invention still further relates to the combination of a compound of the invention together with a gastroprotective H₂ receptor antagonist or the proton pump inhibitors (such as omeprazole)

30 The present invention still further relates to the combination of a compound of the invention together with an α_1 - and α_2 -adrenoceptor agonist vasoconstrictor sympathomimetic agent, including propylhexedrine, phenylephrine, phenylpropanolamine, pseudoephedrine, naphazoline hydrochloride, oxymetazoline hydrochloride, tetrahydrozoline hydrochloride, xylometazoline hydrochloride, and

ethylnorepinephrine hydrochloride.

The present invention still further relates to the combination of a compound of the invention together with anticholinergic agents including ipratropium bromide; tiotropium bromide; oxitropium bromide; pirenzepine; and telenzepine.

The present invention still further relates to the combination of a compound of the invention together with a β_1 - to β_4 -adrenoceptor agonists including metaproterenol isoproterenol, isoprenaline, albuterol, salbutamol, formoterol, salmeterol, terbutaline, orciprenaline, bitolterol mesylate, and pирbutерол; or methylxanthanines including theophylline and aminophylline; sodium cromoglycate; or muscarinic receptor (M1, M2, and M3) antagonist.

The present invention still further relates to the combination of a compound of the invention together with other modulators of chemokine receptor function such as CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10 and CCR11 (for the C-C family); CXCR1, CXCR3, CXCR4 and CXCR5 (for the C-X-C family) and CX₃CR1 for the C-X₃-C family.

The present invention still further relates to the combination of a compound of the invention together with an insulin-like growth factor type I (IGF-1) mimetic.

The present invention still further relates to the combination of compound of the invention together with an inhaled glucocorticoid with reduced systemic side effects, including prednisone, prednisolone, flunisolide, triamcinolone acetonide, beclomethasone dipropionate, budesonide, fluticasone propionate, and mometasone furoate.

The present invention still further relates to the combination of a compound of the invention together with (a) tryptase inhibitors; (b) platelet activating factor (PAF) antagonists; (c) interleukin converting enzyme (ICE) inhibitors; (d) IMPDH inhibitors; (e)

adhesion molecule inhibitors including VLA-4 antagonists; (f) cathepsins; (g) MAP kinase inhibitors; (h) glucose-6 phosphate dehydrogenase inhibitors; (i) kinin-B₁ - and B₂ - receptor antagonists; (j) anti-gout agents, e.g., colchicine; (k) xanthine oxidase inhibitors, e.g., allopurinol; (l) uricosuric agents, e.g., probenecid, sulfinpyrazone, and 5 benz bromarone; (m) growth hormone secretagogues; (n) transforming growth factor (TGF β); (o) platelet-derived growth factor (PDGF); (p) fibroblast growth factor, e.g., basic fibroblast growth factor (bFGF); (q) granulocyte macrophage colony stimulating factor (GM-CSF); (r) capsaicin cream; (s) Tachykinin NK₁ and NK₃ receptor antagonists selected from the group consisting of NKP-608C; SB-233412 (talnetant); and D-4418; and (t) 10 elastase inhibitors selected from the group consisting of UT-77 and ZD-0892 (u) induced nitric oxide synthase inhibitors (iNOS) or (v) chemoattractant receptor-homologous molecule expressed on TH2 cells, (CRTH2 antagonists).

The present invention still further relates to the combination of a compound of the 15 invention together with an inhibitor of matrix metalloproteases (MMPs), i.e., the stromelysins, the collagenases, and the gelatinases, as well as aggrecanase; especially collagenase-1 (MMP-1), collagenase-2 (MMP-8), collagenase-3 (MMP-13), stromelysin-1 (MMP-3), stromelysin-2 (MMP-10), and stromelysin-3 (MMP-11).

20 The compounds of the invention can also be used in combination with existing therapeutic agents for the treatment of osteoarthritis. Suitable agents to be used in combination include standard non-steroidal anti-inflammatory agents (hereinafter NSAID's) such as piroxicam, diclofenac, propionic acids such as naproxen, flubiprofen, fenoprofen, ketoprofen and ibuprofen, fenamates such as mefenamic acid, indomethacin, sulindac, apazone, 25 pyrazolones such as phenylbutazone, salicylates such as aspirin, induced nitric oxide synthase inhibitors (iNOS inhibitors), COX-2 inhibitors such as celecoxib, valdecoxib, rofecoxib and etoricoxib, and the cyclo-oxygenase inhibiting nitric oxide donors (CINOD's) analgesics (such as paracetamol and tramadol), cartilage sparing agents such as diacerein, doxycycline and glucosamine, and intra-articular therapies such as corticosteroids 30 and hyaluronic acids such as hyalgan and synvisc.

The compounds of the invention can also be used in combination with existing therapeutic agents for the treatment of inflammatory bowel diseases (Ulcerative colitis and Crohn's disease). Suitable agents to be used include sulphasalazine, 5-amino-salicylates, the thiopurines, azathioprine and 6-mecaptourine and corticosteroids such as budesonide.

The compounds of the present invention may also be used in combination with anticancer agents such as endostatin and angiostatin or cytotoxic drugs such as adriamycin, daunomycin, cis-platinum, etoposide, taxol, taxotere and farnesyl transferase inhibitors, 10 VegF inhibitors, COX-2 inhibitors and antimetabolites such as methotrexate, antineoplastic agents, especially antimitotic drugs including the vinca alkaloids such as vinblastine and vincristine.

The compounds of the invention may also be used in combination with antiviral agents 15 such as Viracept, AZT, aciclovir and famciclovir, and antisepsis compounds such as Valant.

The compounds of the present invention may also be used in combination with 20 cardiovascular agents such as calcium channel blockers, lipid lowering agents such as statins, fibrates, beta-blockers, Ace inhibitors, Angiotensin-2 receptor antagonists and platelet aggregation inhibitors.

The compounds of the present invention may also be used in combination with CNS agents such as antidepressants (such as sertraline), anti-Parkinsonian drugs (such as deprenyl, L- 25 dopa, Requip, Mirapex, MAOB inhibitors such as selegiline and rasagiline, comP inhibitors such as Tasmar, A-2 inhibitors, dopamine reuptake inhibitors, NMDA antagonists, Nicotine agonists, Dopamine agonists and inhibitors of neuronal nitric oxide synthase), and anti Alzheimer's drugs such as donepezil, tacrine, COX-2 inhibitors, propentofylline or metryfonate.


The compounds of the present invention may also be used in combination with osteoporosis agents such as roloxifene, droloxifene, lasofoxifene or fosomax and immunosuppressant agents such as FK-506, rapamycin, cyclosporine, azathioprine, and methotrexate.

5

The present invention will now be further explained by reference to the following illustrative examples. In the examples the NMR spectra were measured on a Varian Unity spectrometer at a proton frequency of either 300 or 400MHz. The MS spectra were measured on either a Agilent 1100 MSD G1946D spectrometer or a Hewlett Packard 10 HP1100 MSD G1946A spectrometer. Preparative HPLC separations were performed using a Waters' SymmetryTM or XterraTM column or a NovapakTM column.

Example 1

15 **2-Chloro-5-[(3S)-3-hydroxy-4-(methylamino)butyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide, hydrochloride**



a) **5-Ethenyl-2,2,3,3,8,8,9,9-octamethyl-(5S) 4,7-dioxa-3,8-disiladecane**

Imidazole (4g) was added portionwise to a solution of (2S)-3-butene-1,2-diol (2g) and chloro(1,1-dimethylethyl)dimethyl-silane (7g) in *N,N*-dimethylformamide (20 mL). The 20 mixture was stirred at room temperature for 24 hours. The biphasic reaction mixture was poured into ether and washed with water (x3) and brine, dried over anhydrous magnesium sulfate, filtered and evaporated, to give an oil (7.5g). Purification by bulb-bulb distillation (130-150°C at 3mm Hg), gave the sub-titled compound as an oil (5.3g).

¹H NMR (300 MHz, CDCl₃) δ 5.92 - 5.81 (1H, m), 5.26 (1H, d), 5.11 (1H, d), 4.16 (1H, q), 3.57 - 3.42 (2H, m), 0.90 (18H, s), 0.05 (12 H,s).

b) 2-Chloro-5-[(3*S*)-3,4-dihydroxybutyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide

9-Borabicyclo[3.3.1]nonane dimer (1.8g) was added at room temperature to a solution of 5-ethenyl-2,2,3,3,8,8,9,9-octamethyl-(5*S*) 4,7-dioxa-3,8-disiladecane (Example 1 a) (1.0g) in tetrahydrofuran (20 mL), under nitrogen. *N,N*-dimethylformamide (20 mL) was added to the reaction mixture and degassed by bubbling nitrogen through the reaction mixture for 30 minutes. A solution of 2-chloro-5-iodo-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide (1.3g) (prepared as described in WO99/29661) in *N,N*-dimethylformamide (10 mL) was added to the reaction mixture and degassing continued for 45min. Potassium carbonate (1.0g) and *tetrakis*(triphenylphosphine)palladium(0) (0.2g) were added to the reaction mixture and heated to 80-90°C for 24 hours under nitrogen. On cooling to room temperature the reaction mixture was poured into ethyl acetate and the organic layer washed with water, aqueous hydrochloric acid (2M), brine, dried over anhydrous magnesium sulfate, filtered and evaporated. The resulting oil was redissolved in dichloromethane (50 mL) and hydrochloric acid in 1,4-dioxane (4M, 5 mL) was added. After 18 hours the reaction mixture was concentrated and purified by column chromatography (gradient 0-5% methanol in dichloromethane). Further purification by reverse phase HPLC (gradient 25-95% acetonitrile (MeCN) in 0.2% aqueous ammonium acetate (NH₄AcO) on Symmetry™ column) gave the sub-titled product as a white solid (0.36g).

¹H NMR (300 MHz, CDCl₃) δ 7.57 (1H, d), 7.31 (1H, d), 7.20 (1H, dd), 6.30 (1H, s), 3.76 - 3.56 (2H, m), 3.46 (1H, t), 3.18 (2H, d), 2.87 - 2.66 (2H, m), 2.34 (1H, s), 2.07 - 1.91 (4H, m), 1.80 - 1.54 (14H, m).

MS (APCI+) ion [M+H]⁺ 392/4

m.p. 145-147 °C

$[\alpha]_D^{25}$ (C=0.16 in MeOH) -16.4°

c) 2-Chloro-5-[(3*S*)-3-hydroxy-4-[(methylsulfonyl)oxy]butyl]-*N*-
5 (tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide

Methanesulfonylchloride (0.08 mL) was added to a solution of 2-chloro-5-[(3*S*)-3,4-dihydroxybutyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide (Example 1 b) (0.33g) and triethylamine (0.33 ml) in dichloromethane (10 mL). After 1 hour the reaction mixture was concentrated, redissolved in ethyl acetate and the organic layer washed with water, 10 brine, dried over anhydrous magnesium sulfate, filtered and evaporated. Purification by normal phase HPLC (gradient 0-5% ethanol (EtOH) in dichloromethane on silica Novapak™ column), gave the sub-titled compound (0.14g).

15 ¹H NMR (300 MHz, CDCl₃) δ 7.57 (1H, d), 7.33 (1H, d), 7.20 (1H, dd), 6.31 (1H, s), 4.25 - 4.09 (2H, m), 3.96 - 3.81 (1H, m), 3.18 (2H, d), 3.06 (3H, s), 2.93 - 2.65 (2H, m), 2.30 (1H, d), 2.01 (3H, s), 1.87 - 1.57 (14H, m).

20 MS (APCI+) ion [M+H]⁺ 470/2

d) 2-Chloro-5-[(3*S*)-3-hydroxy-4-(methylamino)butyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide

25 Aqueous methylamine (40%) (3 mL) was added to a solution of 2-chloro-5-[(3*S*)-3-hydroxy-4-[(methylsulfonyl)oxy]butyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide (Example 1 c) (0.13g) in acetonitrile (20 mL) and heated at 50°C for 4 hours. Further aqueous methylamine (40%) (2 mL) was added and heating at 50°C continued for a further 1 hour. On cooling the reaction mixture was concentrated and purified by solid phase extraction on Waters' SCX resin, eluting with ammonia in methanol (7M). The residue was dissolved in methanol (5 mL) and hydrochloric acid in dioxane (4M, 1 mL) was added, evaporation gave the titled compound (0.12g).

¹H NMR (300 MHz, d₆-DMSO) δ 8.69 - 8.37 (2H, m), 8.29 (1H, t), 7.39 (1H, d), 7.31 - 7.22 (2H, m), 5.60 - 5.21 (1H, m), 3.81 - 3.65 (1H, m), 3.07 - 2.88 (3H, m), 2.88 - 2.57 (3H, m), 2.54 (3H, s), 1.95 (3H, s), 1.75 - 1.55 (8H, m), 1.52 (6H, s).


MS (APCI+) ion [M+H]⁺ 405/7

m.p. >200 °C dec

[α]_D²¹ (C=0.15 in MeOH) -2.4°

Example 2

2-Chloro-5-[(3S)-3-hydroxy-4-(ethylamino)butyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide, hydrochloride




Aqueous ethylamine (70%) (2 mL) was added to a solution of 2-chloro-5-[(3S)-3-hydroxy-4-[(methylsulfonyl)oxy]butyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide (Example 1 c) (0.2 g) in acetonitrile (5 mL) and heated at 50°C for 2.5 hours. On cooling the reaction mixture was concentrated and purified by solid phase extraction on Waters' SCX resin, eluting with ammonia in methanol (7M). Further purification by reverse phase HPLC (gradient 25-95% acetonitrile in 0.2% aqueous trifluoroacetic acid (TFA) on SymmetryTM column). The residue was dissolved in methanol (5 mL) and hydrochloric acid in 1,4-dioxane (4M, 1 mL) was added, evaporation and recrystallisation from acetonitrile, gave the titled compound (0.13g).

¹H NMR (300 MHz, d₆-DMSO) δ 8.74 - 8.32 (2H, m), 8.30 (1H, t), 7.39 (1H, d), 7.33 - 7.21 (2H, m), 5.46 (1H, d), 3.84 - 3.68 (1H, m), 3.05 - 2.85 (5H, m), 2.85 - 2.55 (3H, m), 1.94 (3H, s), 1.79 - 1.55 (8H, m), 1.52 (6H, s), 1.19 (3H, t).

MS (APCI+) ion $[M+H]^+$ 419/421

Example 3

2-Chloro-5-[(3*S*)-3-hydroxy-4-(1-methylethylamino)butyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide, hydrochloride




1-Methylethylamine (3 mL) was added to a solution of 2-chloro-5-[(3*S*)-3-hydroxy-4-[(methylsulfonyl)oxy]butyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide (Example 1 c) (0.22g) in acetonitrile (10 mL) and heated at 50°C for 18 hours. On cooling the reaction mixture was concentrated and purified by solid phase extraction on Waters' SCX resin, eluting with ammonia in methanol (7M). Further purification by reverse phase HPLC (gradient 25-95% acetonitrile in 0.2% aqueous trifluoroacetic acid on Symmetry™ column). The residue was dissolved in methanol (5 mL) and hydrochloric acid in dioxane (4M, 1 mL) was added, evaporation and recrystallisation from MeCN, gave the titled compound as the hydrochloric acid salt (30mg).

¹H NMR (300 MHz, d₆-DMSO) δ 8.70 - 8.21 (3H, m), 7.40 (1H, d), 7.30 - 7.25 (2H, m), 5.44 (1H, d), 3.83 - 3.67 (1H, m), 3.38 - 3.19 (1H, m), 3.05 - 2.86 (3H, m), 2.87 - 2.55 (3H, m), 1.93 (3H, s), 1.77 - 1.47 (14H, m), 1.24 (3H, d), 1.22 (3H, d).

MS (APCI+) ion $[M+H]^+$ 433/435

Example 4

2-Chloro-5-[(3*R*)-3-hydroxy-4-(methylamino)butyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide



5 a) **5-Ethenyl-2,2,3,3,8,8,9,9-octamethyl-(5*R*) 4,7-dioxa-3,8-disiladecane**

The sub-titled compound was prepared by the method of Example 1(a) using (2*R*)-3-butene-1,2-diol.

10 ¹H NMR (300 MHz, CDCl₃) δ 5.92 - 5.81 (1H, m), 5.26 (1H, d), 5.11 (1H, d), 4.16 (1H, q), 3.57 - 3.42 (2H, m), 0.90 (18H, s), 0.05 (12H, s).

b) **2-Chloro-5-[(3*R*)-3,4-dihydroxybutyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide**

The sub-titled compound was prepared by the method of Example 1(b) using 5-ethenyl-2,2,3,3,8,8,9,9-octamethyl-(5*R*) 4,7-dioxa-3,8-disiladecane (product of Example 4a).

15 ¹H NMR (300 MHz, CDCl₃) δ 7.57 (1H, d), 7.31 (1H, d), 7.20 (1H, dd), 6.30 (1H, s), 3.76 - 3.56 (2H, m), 3.46 (1H, t), 3.18 (2H, d), 2.87 - 2.66 (2H, m), 2.44 (1H, s), 2.07 (1H, s), 2.01 (3H, s), 1.80 - 1.54 (14H, m).

20 MS (APCI+) ion [M+H]⁺ 392/4
 $[\alpha]_{D}^{24}$ (C=0.26 in MeOH) +14.0°

25 c) **2-Chloro-5-[(3*R*)-3-hydroxy-4-[(methylsulfonyl)oxy]butyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide**

The sub-titled compound was prepared by the method of Example 1(c) using 2-chloro-5-[(3*R*)-3,4-dihydroxybutyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide.

¹H NMR (300 MHz, CDCl₃) δ 7.57 (1H, d), 7.33 (1H, d), 7.20 (1H, dd), 6.31 (1H, s),
4.25 - 4.09 (2H, m), 3.96 - 3.81 (1H, m), 3.18 (2H, d), 3.06 (3H, s), 2.93 - 2.65 (2H, m),
2.40 (1H, s), 2.01 (3H, s), 1.87 - 1.57 (14H, m).

MS (APCI+) ion [M+H]⁺ 470/2

d) 2-Chloro-5-[(3*R*)-3-hydroxy-4-(methylamino)butyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide


The titled compound was prepared by the method of Example 1(d) using 2-chloro-5-[(3*R*)-3-hydroxy-4-[(methylsulfonyl)oxy]butyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide.

¹H NMR (300 MHz, DMSO) δ 8.69 - 8.37 (2H, m), 8.29 (1H, t), 7.39 (1H, d), 7.31 - 7.22 (2H, m), 5.60 - 5.21 (1H, m), 3.81 - 3.65 (1H, m), 3.07 - 2.88 (3H, m), 2.88 - 2.57 (3H, m), 2.54 (3H, s), 1.95 (3H, s), 1.75 - 1.55 (8H, m), 1.52 (6H, s).

MS (APCI+) ion [M+H]⁺ 405/7

Example 5

20 2-Chloro-5-[(2*R*)-3-(ethylamino)-2-hydroxypropyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide, hydrochloride



a) 2-Chloro-5-(2-propenyl)-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide

2-Chloro-5-iodo-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide

(prepared as described in WO 99/29661) (7.74g), tri-n-butylallyltin (5.99g),

dichlorobis(triphenylphosphine)palladium(II) (1.24g), triphenylphosphine (1.86g), lithium chloride (6.11g) and *N,N*-dimethylformamide (260 mL) were heated together under nitrogen from 110°C to 130°C over 20 minutes, and then at 130°C for 25 minutes. The mixture was then cooled, poured into brine (500 mL), extracted into ethyl acetate (3 x 250mL), dried over anhydrous magnesium sulfate, filtered and concentrated to give an oil.

10 The crude mixture was purified by column chromatography eluting with 9:1 *isohexane/ethyl acetate* to give the sub-titled compound (5.23g).

15 ¹H NMR (300 MHz, CDCl₃) δ 7.54 (1H, s), 7.33-7.31 (1H, d), 7.20-7.16 (1H, d), 6.25 (1H, br s), 5.99-5.85 (1H, m), 5.13-5.06 (2H, m), 3.39-3.37 (2H, d), 3.19-3.17 (2H, d), 2.01 (3H, br s), 1.76-1.63 (6H, br AB), 1.58 (6H, br s).

MS (ES+) ion [M+H]⁺ 344, 346

b) 2-Chloro-5-(oxiranylmethyl)-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide

2-Chloro-5-(2-propenyl)-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide (Example 5 a)

20 (9.4g), pyrazole (0.45g) and methyltrioxorhenium(VII) (0.40g) were stirred together in dichloromethane (40 mL) under nitrogen, and hydrogen peroxide (27.5% wt. solution in water, 13 mL) was added dropwise. The reaction was then monitored by HPLC/MS and further portions of pyrazole, methyltrioxorhenium(VII) and hydrogen peroxide were added over a period of 2 days until the reaction mixture consisted of a 1:1 mixture of starting 25 material and product. The mixture was then poured into water (500 mL), extracted into dichloromethane (3 x 300 mL), washed with 2M aqueous hydrochloric acid (300 mL), brine (300 mL), saturated aqueous sodium thiosulfate (300 mL), dried over anhydrous magnesium sulfate, filtered and concentrated to give an oil. This was purified by column chromatography eluting with 2:1 *isohexane/ethyl acetate* to give the sub-titled compound 30 (4.71g).

¹H NMR (300 MHz, CDCl₃) δ 7.60 (1H, d), 7.38-7.34 (1H, d), 7.28-7.25 (1H, dd), 6.28 (1H, br t), 3.22-3.18 (2H, d), 3.17-3.11 (1H, m), 2.86-2.79 (3H, m), 2.53-2.52 (1H, m), 2.01 (3H, br s), 1.75-1.64 (6H, br AB), 1.59 (6H, br s).

5 MS (ES+) ion [M+H]⁺ 360, 362

c) 2-Chloro-5-[(2R)-2-oxiranylmethyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide

(1*R*, 2*R*)-(-)-*N,N'*-Bis(3,5-di-*t*-butylsalicydene)-1,2-cyclohexanediaminocobalt(II) (0.30g),
10 acetic acid (0.15 mL) and toluene (3 mL) were stirred together in air for 1.25 hours. The solvents were then removed *in vacuo* and the resultant brown glass was dried under high vaccum for 2 hours. 2-Chloro-5-(oxiranylmethyl)-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide (Example 5 b) (1.14g), water (1.5 mL) and tetrahydrofuran (100 mL) were then added to this and the mixture stirred under nitrogen for 82 hours, concentrated and purified
15 by column chromatography eluting with 2:1 *isohexane/ethyl acetate* to give the sub-titled compound (0.28g).

MS (ES+) ion [M+H]⁺ 360, 362

20 d) 2-Chloro-5-[(2*R*)-3-(ethylamino)-2-hydroxypropyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide, hydrochloride salt

2-Chloro-5-[(2*R*)-2-oxiranylmethyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide (Example 5 c) (452mg), ethylamine (70% aqueous solution, 5 mL) and tetrahydrofuran (15 mL) were heated together at 50°C under nitrogen for 20 hours, cooled and concentrated to give an oil. This was purified by Waters' MCX resin (mixed-mode cation exchanger) and then by column chromatography eluting with 19:1:0.1 dichloromethane/methanol/ammonia. The oil obtained was dissolved in dichloromethane (5 mL) and one molar (1M) ethereal hydrogen chloride (4 mL) was added. The mixture was concentrated to give the sub-titled compound as a solid (415mg).

¹H NMR (400 MHz, d₆-DMSO) δ 8.29-8.26 (1H, t); 7.43-7.40 (1H, d); 7.30-7.28 (2H, m); 5.53-5.52 (1H, d); 3.98 (1H, br m); 2.94-2.82 (5H, m); 2.79-2.67 (3H, m); 1.94 (3H, br s); 1.69-1.58 (6H, br AB); 1.52 (6H, br s); 1.20-1.16 (3H, t).


MS: APCI(+ve) ion [M+H]⁺ 405, 407

5 m.p. 218°C

Example 6

2-Chloro-5-[(2*R*)-2-hydroxy-3-[(1-methylethyl)amino]propyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide, hydrochloride

10



2-Chloro-5-[(2*R*)-2-oxiranylmethyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide (Example 5 c) (133 mg), isopropylamine (3 mL) and 1-methyl-2-pyrrolidinone (5 mL) were heated together at 80°C in a sealed tube for 22 hours, cooled and poured into brine (50 mL), extracted into ethyl acetate (3 x 50 mL), washed with brine (3 x 50 mL), dried over anhydrous magnesium sulfate, filtered and concentrated to give an oil. This was purified 15 by Waters' MCX resin and then by column chromatography eluting with 19:1:0.1 dichloromethane/methanol/ammonia. The oil obtained was dissolved in dichloromethane (5 mL) and 1M ethereal hydrogen chloride (4 mL) was added. The mixture was 20 concentrated to give the titled compound as a solid (85 mg).

¹H NMR (400 MHz, d₆-DMSO) δ 8.29 (1H, br t); 7.43-7.41 (1H, d); 7.31-7.29 (2H, m); 5.52 (1H, br s); 3.99 (1H, br s); 2.98-2.92 (3H, m); 2.83-2.67 (3H, m); 1.94 (3H, br s); 1.69-1.59 (6H, br AB); 1.23-1.20 (6H, m).


MS: APCI(+ve) ion [M+H]⁺ 419, 421

5 m.p. 189°C

Example 7

2-Chloro-5-[(2*R*)-2-hydroxy-3-[(3-hydroxypropyl)amino]propyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide, hydrochloride salt

10



2-Chloro-5-[(2*R*)-2-oxiranylmethyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide (Example 5 c) (133 mg), 3-amino-1-propanol (3 mL) and 1-methyl-2-pyrrolidinone (5 mL) were heated together at 80°C in a sealed tube for 22 hours, cooled and poured into brine (50 mL), extracted into ethyl acetate (3 x 50 mL), washed with brine (3 x 50 mL), dried over anhydrous magnesium sulfate, filtered and concentrated to give an oil. This was purified by Waters' MCX resin and then by column chromatography eluting with 9:1:0.1

15 dichloromethane/methanol/ammonia. This was further purified by reverse phase HPLC (gradient 25-95% acetonitrile in 0.2% aqueous trifluoroacetic acid on XterraTM column).

20 The oil obtained was dissolved in dichloromethane (5 mL) and 1M ethereal hydrogen chloride (4 mL) was added. The mixture was concentrated to give the titled compound as a solid (60 mg).

¹H NMR (400 MHz, d₆-DMSO) δ 8.28 (1H, br t); 7.42-7.40 (1H, d); 7.30-7.28 (2H, m); 5.53 (1H, br s); 4.78 (1H, br s); 4.00 (1H, br s); 3.50-3.45 (2H, br t); 3.00-2.92 (5H, m); 2.81-2.68 (3H, m); 1.94 (3H, br s); 1.76 (2H, br m); 1.69-1.58 (6H, br AB); 1.53 (6H, br s).


5 MS: APCI(+ve) ion [M+H]⁺ 435, 437

M.p. 225°C

Example 8

2-Chloro-5-[(2*R*)-3-(dimethylamino)-2-hydroxypropyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-

10 ylmethyl)-benzamide, hydrochloride



2-Chloro-5-[(2*R*)-2-oxiranylmethyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide

(Example 5 c) (133 mg), dimethylamine (40% solution in water, 3 mL) and 1-methyl-2-pyrrolidinone (5 mL) were heated together at 80°C in a sealed tube for 22 hours, cooled and poured into brine (50 mL), extracted into ethyl acetate (3 x 50 mL), washed with brine (3 x 50 mL), dried over anhydrous magnesium sulfate, filtered and concentrated to give an oil. This was purified by Waters' MCX resin and then by reverse phase HPLC (gradient 25-95% acetonitrile in 0.2% aqueous trifluoroacetic acid on Waters' Xterra™ column).

20 The oil obtained was dissolved in dichloromethane (5 mL) and 1M ethereal hydrogen chloride (4 mL) was added. The mixture was concentrated to give the titled compound as a solid (41 mg).

¹H NMR (400 MHz, d₆-DMSO) δ 8.29-8.26 (1H, t); 7.43-7.41 (1H, d); 7.31-7.29 (2H, m); 5.64 (1H, br s); 4.11 (1H, br s); 3.15-2.98 (2H, m); 2.94-2.93 (2H, d); 2.79-2.66 (7H, m); 1.94 (3H, br s); 1.69-1.58 (6H, br AB); 1.53 (6H, br s).


5 MS: APCI(+ve) ion [M+H]⁺ 405, 407

m.p. 198°C

Example 9

2-Chloro-5-[(1*S*)-1-hydroxy-2-(methylamino)ethyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-

10 ylmethyl)benzamide hydrochloride



a) 2-Chloro-5-ethenyl-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide

15 A solution of 5-bromo-2-chloro-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide (prepared as described in WO 00/61569) (1.0g), *tetrakis*(triphenylphosphine)palladium(0) (96mg) and tributylvinyltin (1.15 mL) in toluene (15 mL) was heated at reflux for 3 hours, then cooled to room temperature, diluted with acetone (30 mL) and treated with cesium fluoride (10% aq, 10 mL) at room temperature for 2 hours. The resulting mixture was filtered through celite with further washing with toluene and concentrated. Water was added and the mixture was extracted with ethyl acetate. The combined organic phases were washed with water, dried over anhydrous magnesium sulfate and concentrated. The resulting oil was purified by column chromatography (ethyl acetate:isohexane 100:1 to 80:20) to give the sub-titled compound as a white solid (0.87g).

¹H NMR (400 MHz, CDCl₃) δ 7.25 (d, 1H), 7.39 (dd, 1H), 7.35 (d, 1H), 6.68 (dd, 1H), 6.25 (s, 1H), 5.78 (d, 1H), 3.33 (d, 1H), 3.17 (d, 2H), 2.01 (s, 3H), 1.73 (d, 3H), 1.65 (d, 3H), 1.60 (s, 6H).

5


b) 2-Chloro-5-[(1*S*)-1-hydroxy-2-(methylamino)ethyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide hydrochloride

m-Chloroperoxybenzoic acid (mCPBA) (50%, 0.44g) was added portionwise over 10 minutes to a solution of 2-chloro-5-ethenyl-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide (Example 9 a)) (0.42 g), (*S,S*)-[*N,N*-*bis*(3,5-di-tertbutylsalicylidene)-1,2-cyclohexanediaminato(2-)]manganese(III) chloride (44mg) and *N*-methylmorpholine (0.74g) in dichloromethane (10 mL) at -78°C. After stirring for 8 hours, a further portion of mCPBA (0.13g) was added and the solution was left to warm slowly to room temperature over 16 hours. Sodium hydroxide (NaOH) (2M) was added, stirred for 1 hour and then methylamine (2M in methanol, 2 mL) was added. After stirring for 24 hours the reaction was concentrated, dichloromethane and water were added, the phases were separated and the aqueous was extracted with dichloromethane. The combined organic phases were dried over anhydrous sodium sulfate and concentrated. The resulting oil was purified by reverse phase HPLC (gradient 25-95% methanol in 1% aqueous trifluoroacetic acid). Further purification was performed by column chromatography (methanol/dichloromethane/ammonia (0.88) 1:20:0.5 to 15:100:0.5) gave an oil. Addition of excess 1M ethereal hydrogen chloride gave the titled compound as a white solid (158mg).

25 ¹H NMR (400 MHz, d₆-DMSO) δ 8.33 (t, 1H), 8.20 (s, 1H), 7.48 (d, 1H), 7.45 (dd, 1H), 7.40 (d, 1H), 6.20 (s, 1H), 4.91 (d, 1H), 3.25-3.40 (m, 1H), 3.08 (dd, 1H), 2.95 (d, 2H), 2.85-2.95 (m, 1H), 2.55 (s, 3H), 1.95 (s, 3H), 1.63 (dd, 6H), 1.52 (s, 6H).

Example 10

2-Chloro-5-[(1*R*)-1-hydroxy-2-(methylamino)ethyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide, hydrochloride




5

The titled compound was prepared by the method of Example 9 b) using (*R,R*)-[*N,N*-bis(3,5-di-tertbutylsalicylidene)-1,2-cyclohexanediaminato(2-)]manganese(III) chloride.

¹H NMR (400 MHz, d₆-DMSO) δ 8.55 (t, 1H), 8.34 (s, 1H), 7.49 (d, 1H), 7.44 (dd, 1H),
 10 7.40 (d, 1H), 6.26 (s, 1H), 4.93 (d, 1H), 3.26-3.40 (m, 1H), 3.11 (dd, 1H), 2.95 (d, 2H),
 2.95 (dd, 1H), 2.57 (s, 3H), 1.94 (s, 3H), 1.64 (dd, 6H), 1.52 (s, 6H).

Example 11

2-Chloro-5-[(1*R*)-2-(ethylamino)-1-hydroxyethyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide




The titled compound was prepared by the method of Example 9b) using (*R,R*)-[*N,N*'-bis(3,5-di-tertbutylsalicylidene)-1,2-cyclohexanediaminato(2-)]manganese(III) chloride and ethylamine.

5 ^1H NMR (400 MHz, d_6 -DMSO) δ 8.30 (1H, t), 7.43-7.32 (3H, m), 5.40 (1H, s), 4.64 (1H, dd), 2.93 (2H, d), 2.68-2.50 (4H, m), 1.94 (3H, s), 1.63 (6H, dd), 1.52 (6H, d), 1.00 (3H, t).

Example 12

2-Chloro-5-[(1*R*)-1-hydroxy-2-[(3-hydroxypropyl)amino]ethyl]-*N*-
10 (tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide




The titled compound was prepared by the method of Example 9b) using (*R,R*)-[*N,N*'-bis(3,5-di-tertbutylsalicylidene)-1,2-cyclohexanediaminato(2-)]manganese(III) chloride
15 and 3-aminopropan-1-ol.

1 ^1H NMR (400 MHz, d_6 -DMSO) δ 7.43-7.32 (3H, m), 5.40 (1H, s), 4.63 (1H, s),
20 3.44 (2H, t), 2.93 (2H, d), 2.66-2.55 (4H, m), 1.94 (3H, s), 1.64 (6H, q), 1.57-1.50 (2H, m),
1.53 (6H, s).

20

Example 13

2-Chloro-5-[(2*S*)-2-hydroxy-3-(methylamino)propyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide, hydrochloride



a) **2-Chloro-5-(2,3-dihydroxypropyl)-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide**

2-Chloro-5-(2-propenyl)-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide (prepared as described in Example 5a) (1.99g), *tert*-butanol (40 mL) and water (40 mL) were stirred together under nitrogen and AD-mix- α was added. The mixture was then stirred at room temperature for 20 hours. Sodium sulfite (2 g) was added and the mixture was stirred for 10 minutes. Water (100 mL) and ethyl acetate (100 mL) were then added. The layers were separated and the aqueous layer was further extracted with ethyl acetate (2 x 100 mL). The combined extracts were dried over anhydrous magnesium sulfate, filtered and concentrated to give the crude product. Purification was performed by column chromatography eluting with 5:95 methanol/ethyl acetate to give the sub-titled compound as a solid (1.77g).

¹H NMR (400 MHz, CDCl₃) δ 7.59 (1H, d); 7.36-7.34 (1H, d); 7.26-7.23 (1H, dd); 6.29 (1H, br t); 3.98-3.91 (1H, m); 3.72-3.67 (1H, m); 3.54-3.48 (1H, m); 3.18-3.17 (2H, d); 2.83-2.73 (2H, m); 2.25-2.24 (1H, d); 2.01 (3H, br s); 1.98-1.95 (1H, t); 1.75-1.64 (6H, br AB); 1.59 (6H, br s).

MS (ES+) ion [M+H]⁺ 378, 380

b) **2-Chloro-5-[(2*S*)-2-oxiranylmethyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide**

2-Chloro-5-(2,3-dihydroxypropyl)-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide (Example 13 a) (1.77 g), triethylamine (0.7 mL), dichloromethane (160 mL) and tetrahydrofuran (40 mL) were cooled to 5°C under nitrogen and methanesulfonyl chloride (0.35 mL) was added. The mixture was then stirred at 5°C for 15 minutes, poured into aqueous sodium bicarbonate solution (75 mL), extracted into dichloromethane (3 x 100 mL), dried over anhydrous magnesium sulfate, filtered and concentrated to give the crude product. This was purified by column chromatography eluting with ethyl acetate to give the mesylate (1.06g). The mesylate (971 mg) in methanol (45 mL) was stirred under nitrogen and potassium carbonate (592 mg) was added. The mixture was then stirred at room temperature for 1 hour, poured into water (50 mL), extracted into ethylacetate (3 x 50 mL), dried over anhydrous magnesium sulfate, filtered and concentrated to give the crude product. This was purified by column chromatography eluting with 2:1 *iso*-hexane/ethylacetate to give the epoxide (595 mg). (1*S*, 2*S*)-(-)-*N,N*-Bis(3,5-di-*t*-butylsalicydene)-1,2-cyclohexanediaminocobalt(II) (0.20g), acetic acid (0.1 mL) and toluene (2 mL) were stirred together in air for 1.5 hours. The solvents were then removed *in vacuo* and the resultant brown glass was dried under high vacuum for 2 hours. The epoxide described above (595 mg), water (1 mL) and tetrahydrofuran (30 mL) were then added to this and the mixture stirred under nitrogen for 92 hours, concentrated and purified by column chromatography eluting with 2:1 *iso*hexane/ethyl acetate to give the sub-titled compound (0.219g).

MS (ES+) ion [M+H]⁺ 360, 362

c) 2-Chloro-5-[(2*S*)-2-hydroxy-3-(methylamino)propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide, hydrochloride salt
2-Chloro-5-[(2*S*)-2-oxiranylmethyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide (Example 13 b) (110mg), methylamine (40% aqueous solution, 2 mL) and tetrahydrofuran (10 mL) were heated together at 50°C under nitrogen for 20 hours, cooled and concentrated to give an oil. This was purified by Waters' MCX resin and then by column chromatography eluting with 9:1:0.1 dichloromethane/methanol/ammonia. The oil

obtained was dissolved in dichloromethane (5 mL) and 1M ethereal hydrogen chloride (4 mL) was added. The resulting white solid was filtered off to give the titled compound (121mg).

5 ^1H NMR (400 MHz, d_6 -DMSO) δ 8.29-8.26 (1H, t); 7.43-7.40 (1H, d); 7.30-7.27 (2H, m); 5.55-5.53 (1H, d); 3.97 (1H, br m); 2.97-2.90 (3H, m); 2.80-2.67 (3H, m); 2.53 (3H, s); 1.94 (3H, br s); 1.69-1.58 (6H, br AB); 1.52 (6H, br s).


MS APCI(+ve) ion $[\text{M}+\text{H}]^+$ 391, 393

m.p. 196°C

10

Example 14

2-Chloro-5-[(2S)-3-(ethylamino)-2-hydroxypropyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide, hydrochloride salt



15

2-Chloro-5-[(2S)-2-oxiranylmethyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide (Example 13 b) (110mg), ethylamine (70% aqueous solution, 2 mL) and tetrahydrofuran (10 mL) were heated together at 50°C under nitrogen for 20 hours, cooled and concentrated to give an oil. This was purified by Waters' MCX resin and then by column chromatography eluting with 9:1:0.1 dichloromethane/methanol/ammonia. The oil obtained was dissolved in dichloromethane (5 mL) and 1M ethereal hydrogen chloride (4

mL) was added. The resulting white solid was filtered off to give the titled compound (109mg).


¹H NMR (400 MHz, d₆-DMSO) δ 8.30-8.27 (1H, t); 7.43-7.40 (1H, d); 7.30-7.28 (2H, m); 5.54-5.53 (1H, d); 3.99 (1H, br m); 3.00-2.87 (5H, m); 2.82-2.67 (3H, m); 1.94 (3H, br s); 1.69-1.58 (6H, br AB); 1.52 (6H, br s); 1.20-1.16 (3H, t).

MS APCI(+ve) ion [M+H]⁺ 405, 407

m.p. 214°C

10 **Example 15**

2-Chloro-5-[(2*R*)-2-hydroxy-3-(methylamino)propyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide, benzoic acid salt



15 **a) 2-Chloro-5-iodo-*N*-(4-methoxyphenyl)methyl-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide**

Potassium t-butoxide (18.8g) was added to a stirred solution of 2-chloro-5-iodo-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide (prepared as described in WO 99/29661) (60.0g) in anhydrous tetrahydrofuran (600 mL) at 20°C under nitrogen. After the addition was complete, 4-methoxybenzyl chloride (20.8 mL) was added. The mixture was heated to reflux for 12 hours and then cooled to room temperature. Water (600 mL) was added and the mixture extracted with dichloromethane (1.2L then 400 mL). Organic extracts were dried over anhydrous magnesium sulphate, filtered and evaporated under reduced pressure.

The residual solid was suspended in *iso*-hexane/*t*-butyl methyl ether (9:1, 1L), stirred at reflux for 1 hour and then cooled to room temperature. The solid was filtered then dried *in vacuo* to give the sub-titled compound (72.88g).

5 ^1H NMR (400 MHz, CDCl_3) (major rotamer only) δ 1.62-1.77 (2H, m), 2.01 (3H, s), 2.73 (1H, d), 3.71 (1H, d), 3.80 (3H, s), 4.38 (2H, ABq), 6.83 (2H, d), 6.92 (2H, d), 7.10 (1H, d), 7.42 (1H, d), 7.55 (1H, dd).

MS (APCI) ion $[\text{M}+\text{H}]^+$ 550/552

10 b) 2-Chloro-5-[(2*S*)-3-chloro-2-hydroxypropyl]-*N*-(4-methoxyphenyl)methyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide

iso-Propylmagnesium chloride solution (2M in tetrahydrofuran, 72.9 mL) was added to a stirred solution of 2-chloro-5-iodo-*N*-(4-methoxyphenyl)methyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide (Example 15 a) (72.87g) in anhydrous tetrahydrofuran (1 L) at 0°C under nitrogen. After 30 minutes, copper(I) bromide dimethylsulphide complex (0.68g) followed by (*R*)-(-)epichlorohydrin (11.4 mL) were added. The mixture was warmed to 30°C for 2 hours then diluted with saturated sodium bicarbonate solution (1 L) and water (500 mL) then extracted with ethyl acetate (2 \times 1L). Organic extracts were dried over anhydrous magnesium sulphate, filtered and evaporated under reduced pressure. The residual oil was dissolved in methanol (600 mL), stirred overnight and the precipitated solid filtered and dried *in vacuo* to give the titled compound (52.25g).

25 ^1H NMR (400 MHz, CDCl_3) (major rotamer only) δ 1.50-1.78 (2H, m), 2.01 (3H, s), 2.63 (1H, dd), 2.68-2.84 (2H, m), 3.24-3.30 (1H, m), 3.40 (1H, dt), 3.76-3.88 (5H, m), 4.40 (2H, ABq), 6.82 (2H, d), 6.95 (2H, d), 7.05 (1H, d), 7.12 (1H, dd), 7.31 (1H, d).

MS (APCI) ion $[\text{M}+\text{H}]^+$ 516/518/520

30 c) 2-Chloro-5-[(2*R*)-2-hydroxy-3-(methylamino)propyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide

A solution of 2-chloro-5-[(2S)-3-chloro-2-hydroxypropyl]-N-[(4-methoxyphenyl)methyl]-
N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide (Example 15b)) (52.24g, 101mmol) in
trifluoroacetic acid (260 mL) was heated at 50°C for 16 hours then evaporated to a viscous
oil. The oil was redissolved in methanol (500 mL) and evaporated *in vacuo*. The residual
5 solid was dissolved in tetrahydrofuran (300 mL) and a solution of sodium hydroxide
(8.08g) in methanol (100 mL) was added. After 15 minutes, 40 wt % aqueous
methylamine solution (520 mL) was added. After 2 hours, the solution was decanted from
a brown oil and evaporated under reduced pressure at 50°C. The resulting suspension was
diluted with water (2 L), acidified to pH<2 with 37 wt % hydrochloric acid, and extracted
10 with ethyl acetate (1 L). The organic layer was back-extracted with 0.5M hydrochloric
acid (1 L). Combined aqueous extracts were adjusted to pH 11-12 with 50 wt % sodium
hydroxide solution, and extracted with ethyl acetate (2 × 1L). Organic extracts were dried
over anhydrous magnesium sulphate, filtered and evaporated under reduced pressure to
give the titled compound as a white solid (34.52g).

15

¹H NMR (400 MHz, CDCl₃) δ 1.59 (6H, s), 1.65 (3H, d), 1.73 (3H, d), 2.01 (3H, s), 2.42
(3H, s), 2.49 (1H, t), 2.68 (1H, dd), 2.71 (2H, d), 3.17 (2H, d), 3.80-3.87 (1H, m), 6.29
(1H, s), 7.25 (1H, d), 7.33 (1H, d), 7.58 (1H, s).

MS (APCI) ion [M+H]⁺ 510, 512

20

d) 2-Chloro-5-[(2R)-2-hydroxy-3-(methylamino)propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-
ylmethyl)benzamide benzoic acid salt

Benzoic acid (11.07g) was added to a suspension of 2-chloro-5-[(2R)-2-hydroxy-3-
(methylamino)propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide (Example 15 c))

25 (33.54g, 86mmol) in 2-propanol (333 mL) and the mixture heated to reflux whereupon a
clear solution was obtained. *t*-Butyl methyl ether (1 L) was added dropwise over 30
minutes and the solution maintained at reflux. The solution was allowed to cool to room
temperature, stirred for a further 2 hours and solid collected by filtration, washed with
30 *t*-butyl methyl ether and dried *in vacuo* at 40°C to give the titled compound (24.5g). The
mother liquors were evaporated *in vacuo* and the residue dissolved in 2-propanol (50 mL)

at reflux, *t*-butyl methyl ether (150 mL) was added and a second crop was isolated as before to give further titled compound (13g).

¹H NMR (400 MHz, d₆-DMSO) δ 1.52 (6H, s), 1.59 (3H, d), 1.67 (3H, d), 1.94 (3H, s),
2.43 (3H, s), 2.60-2.68 (2H, m), 2.72-2.79 (2H, m), 2.93 (2H, d), 3.88-3.93 (1H, m), 7.26
(1H, s), 7.27 (1H, d), 7.35-7.40 (3H, m), 7.47 (1H, t), 7.90 (2H, d), 8.29 (1H, t).
MS (APCI) ion [M+H]⁺ 391, 393

Pharmacological Analysis

10 Certain compounds such as benzoylbenzoyl adenosine triphosphate (bbATP) are known to be agonists of the P2X₇ receptor, effecting the formation of pores in the plasma membrane (Drug Development Research (1996), 37(3), p.126). Consequently, when the receptor is activated using bbATP in the presence of ethidium bromide (a fluorescent DNA probe), an increase in the fluorescence of intracellular DNA-bound ethidium bromide is observed.


15 The increase in fluorescence can be used as a measure of P2X₇ receptor activation and therefore to quantify the effect of a compound on the P2X₇ receptor.

In this manner, each of the title compounds of the Examples was tested for antagonist activity at the P2X₇ receptor. Thus, the test was performed in 96-well flat bottomed 20 microtitre plates, the wells being filled with 250 μl of test solution comprising 200 μl of a suspension of THP-1 cells (2.5 x 10⁶ cells/ml) containing 10⁻⁴M ethidium bromide, 25 μl of a high potassium buffer solution containing 10⁻⁵M bbATP, and 25 μl of the high potassium buffer solution containing 3 x 10⁻⁵M test compound. The plate was covered with a plastics sheet and incubated at 37 °C for one hour. The plate was then read in a 25 Perkin-Elmer fluorescent plate reader, excitation 520 nm, emission 595 nm, slit widths: Ex 15 nm, Em 20 nm. For the purposes of comparison, bbATP (a P2X₇ receptor agonist) and pyridoxal 5-phosphate (a P2X₇ receptor antagonist) were used separately in the test as controls. From the readings obtained, a pIC₅₀ figure was calculated for each test compound, this figure being the negative logarithm of the concentration of test compound 30 necessary to reduce the bbATP agonist activity by 50%. Each of the compounds of the

Examples demonstrated antagonist activity, having a pIC_{50} figure > 4.50 . For example, the compounds of Examples 1, 8 and 10 had pIC_{50} values of 8.0, 8.4 and 8.2 respectively.

CLAIMS

1. A compound of formula




5 wherein m represents 1, 2 or 3;
 each R¹ independently represents a hydrogen or halogen atom;
 one of R² and R³ represents halogen, nitro, amino, hydroxyl, or a group
 selected from (i) C₁-C₆ alkyl optionally substituted by at least one halogen atom,
 (ii) C₃-C₈ cycloalkyl, (iii) C₁-C₆ alkoxy optionally substituted by at least one halogen
 10 atom, and (iv) C₃-C₈ cycloalkyloxy, and the other of R² and R³ represents a hydrogen or
 halogen atom;
 n represents 0, 1 or 2; and
 R⁴ and R⁵ each independently represent a hydrogen atom or a C₁-C₆ alkyl group optionally
 substituted by at least one substituent selected from hydroxyl, halogen and C₁-C₆ alkoxy;
 15 or a pharmaceutically acceptable salt or solvate thereof.

2. A compound according to claim 1, wherein m is 1.

3. A compound according to claim 1 or claim 2, wherein R³ represents a hydrogen
 20 atom.

4. A compound according to any one of claims 1 to 3, wherein n is 1.

5. A compound according to claim 4, which has the following stereochemistry:



5

6. A compound according to any one of claims 1 to 5, wherein R⁴ and R⁵ each independently represent a hydrogen atom or a C₁-C₆ alkyl group optionally substituted by at least one hydroxyl group.

10 7. A compound according to claim 1, wherein

m represents 1;

each R¹ represents a hydrogen atom;

one of R² and R³ represents a halogen atom, and the other of R² and R³ represents a hydrogen atom;

15 n is 0, 1 or 2; and

R⁴ and R⁵ each independently represent a hydrogen atom or a group selected from -CH₃, -C₂H₅, -CH(CH₃)₂ and -(CH₂)₃OH.

8. A compound according to claim 1, wherein

20 m represents 1;

each R¹ represents a hydrogen atom;

one of R² and R³ represents a halogen atom, and the other of R² and R³ represents a hydrogen atom;

n is 0, 1 or 2; and

one of R⁴ and R⁵ represents a hydrogen atom or -CH₃ and the other of R⁴ and R⁵ represents a group selected from -CH₃, -C₂H₅, -CH(CH₃)₂ and -(CH₂)₃OH.

5 9. A compound being selected from any one of:

2-Chloro-5-[(3S)-3-hydroxy-4-(methylamino)butyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide,

2-Chloro-5-[(3S)-3-hydroxy-4-(ethylamino)butyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide,

10 2-Chloro-5-[(3S)-3-hydroxy-4-(1-methylethylamino)butyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide,

2-Chloro-5-[(3R)-3-hydroxy-4-(methylamino)butyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide,

15 2-Chloro-5-[(2R)-3-(ethylamino)-2-hydroxypropyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide hydrochloride,

2-Chloro-5-[(2R)-3-(ethylamino)-2-hydroxypropyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide,

2-Chloro-5-[(2R)-2-hydroxy-3-[(1-methylethyl)amino]propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide hydrochloride,

20 2-Chloro-5-[(2R)-2-hydroxy-3-[(1-methylethyl)amino]propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide,

2-Chloro-5-[(2R)-2-hydroxy-3-[(3-hydroxypropyl)amino]propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide hydrochloride,

25 2-Chloro-5-[(2R)-2-hydroxy-3-[(3-hydroxypropyl)amino]propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide,

2-Chloro-5-[(2R)-3-(dimethylamino)-2-hydroxypropyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide hydrochloride,

2-Chloro-5-[(2R)-3-(dimethylamino)-2-hydroxypropyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide,

2-Chloro-5-[(1S)-1-hydroxy-2-(methylamino)ethyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide hydrochloride,

2-Chloro-5-[(1S)-1-hydroxy-2-(methylamino)ethyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide,

5 2-Chloro-5-[(1R)-1-hydroxy-2-(methylamino)ethyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide hydrochloride,

2-Chloro-5-[(1R)-1-hydroxy-2-(methylamino)ethyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide,

10 2-Chloro-5-[(1R)-2-(ethylamino)-1-hydroxyethyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide,

2-Chloro-5-[(1R)-1-hydroxy-2-[(3-hydroxypropyl)amino]ethyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide,

2-Chloro-5-[(2S)-2-hydroxy-3-(methylamino)propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide hydrochloride,

15 2-Chloro-5-[(2S)-2-hydroxy-3-(methylamino)propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide,

2-Chloro-5-[(2S)-3-(ethylamino)-2-hydroxypropyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide hydrochloride,

20 2-Chloro-5-[(2S)-3-(ethylamino)-2-hydroxypropyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide,


2-Chloro-5-[(2R)-2-hydroxy-3-(methylamino)propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide benzoic acid salt,

2-Chloro-5-[(2R)-2-hydroxy-3-(methylamino)propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide,

25 and all pharmaceutically acceptable salts and solvates thereof.


10. A process for the preparation of a compound according to claim 1, which comprises:

(i) when n is 0, reacting a compound of formula




wherein m , R^1 , R^2 and R^3 are as defined in formula (I), with a compound of formula (III), HNR^4R^5 , wherein R^4 and R^5 are as defined in formula (I); or

5 (ii) when n is 1, reacting a compound of formula




wherein m , R^1 , R^2 and R^3 are as defined in formula (I), with a compound of formula (III) as defined in (i) above; or

10 (iii) when n is 2, reacting a compound of formula



wherein L¹ is a leaving group and m, R¹, R² and R³ are as defined in formula (I), with a compound of formula (III) as defined in (i) above; or

5 (iv) when n is 1, reacting a compound of formula



10 wherein L² is a leaving group and m, R¹, R² and R³ are as defined in formula (I), with a compound of formula (III) as defined in (i) above;

11 and optionally after (i), (ii) (iii) or (iv) carrying out one or more of the following:

- converting the compound obtained to a further compound of formula (I)
- forming a pharmaceutically acceptable salt or solvate of the compound.

11. A pharmaceutical composition comprising a compound of formula (I) or a

15 pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 9 in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

12. A process for the preparation of a pharmaceutical composition as claimed in claim 11 which comprises mixing a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as defined in any one of claims 1 to 9 with a pharmaceutically acceptable adjuvant, diluent or carrier.

5

13. A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 9 for use in therapy.

14. Use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 9 in the manufacture of a medicament for use in the treatment of rheumatoid arthritis.

15. Use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 9 in the manufacture of a medicament for use in the treatment of an obstructive airways disease.

16. Use according to claim 15, wherein the obstructive airways disease is asthma or chronic obstructive pulmonary disease.

20 17. Use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 9 in the manufacture of a medicament for use in the treatment of osteoarthritis.

25 18. Use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 9 in the manufacture of a medicament for use in the treatment of atherosclerosis.

19. A method of treating rheumatoid arthritis or osteoarthritis which comprises administering to a patient a therapeutically effective amount of a compound of formula (I)

or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 9.

20. A method of treating an obstructive airways disease which comprises administering to a patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 9.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE 2004/000227

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07C 13/615, A61P 37/00, A61P 29/00, A61K 31/166
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07C, A61K, A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-INTERNAL, WPI DATA, PAJ, CHEM.ABS.DATA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2003/0013704 A (LILLIAN ALCARAZ ET AL), 16 January 2003 (16.01.2003), claims 1-22 --	1-20
X	US 6492355 B1 (LILLIAN ALCARAZ ET AL), 10 December 2002 (10.12.2002), claims 1-12 --	1-20
X	US 2001/0003121 A (ANDREW BAXTER ET AL), 7 June 2001 (07.06.2001), claims 1-12 --	1-20
X	US 6201024 B1 (ANDREW BAXTER ET AL), 13 March 2001 (13.03.2001), claims 1-9 --	1-20

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:	
"A"	document defining the general state of the art which is not considered to be of particular relevance
"E"	earlier application or patent but published on or after the international filing date
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O"	document referring to an oral disclosure, use, exhibition or other means
"P"	document published prior to the international filing date but later than the priority date claimed
"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X"	document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y"	document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&"	document member of the same patent family

Date of the actual completion of the international search

10 May 2004

Date of mailing of the international search report

18-05-2004

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. + 46 8 666 02 86

Authorized officer

Johanna Brolund/Els
Telephone No. + 46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE 2004/000227

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6242470 B1 (ANDREW BAXTER ET AL), 5 June 2001 (05.06.2001), claims 1-11 --	1-20
A	US 2002/0193414 A (LILLIAN ALCARAZ ET AL), 19 December 2002 (19.12.2002), claims 1-21 --	1-20
P,A	WO 03041707 A1 (ASTRAZENECA-AB), 22 May 2003 (22.05.2003), claims 1-23 --	1-20
P,A	US 2003/0144293 A (ALLEN J. DUPLANTIER), 31 July 2003 (31.07.2003), claims 1-23 --	1-20
P,A	EP 1310493 A1 (PFIZER PRODUCTS INC.), 14 May 2003 (14.05.2003), claims 1-12 -----	1-20

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE 2004/000227

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: **19–20**
because they relate to subject matter not required to be searched by this Authority, namely:
see next page
2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE 2004/000227

Claims 19-20 relate to methods of treatment of the human or animal body by surgery or by therapy, / Rule 39.1(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE 2004/000227

US 2003/0013704 A 16/01/2003 NONE

US	6492355	B1	10/12/2002	AU	3994700	A	14/11/2000
				AU	5547000	A	02/01/2001
				BR	0009651	A	08/01/2002
				CA	2368829	A	19/10/2000
				CN	1353702	T	12/06/2002
				CZ	20013608	A	15/05/2002
				EE	200100525	A	16/12/2002
				EP	1171432	A	16/01/2002
				GB	0002330	D	00/00/0000
				HU	0202214	A	28/10/2002
				IL	145505	D	00/00/0000
				JP	2002541249	T	03/12/2002
				NO	20014894	A	10/12/2001
				NZ	514477	A	29/04/2003
				PL	350907	A	10/02/2003
				SK	13422001	A	09/05/2002
				TR	200102911	T	00/00/0000
				WO	0061569	A	19/10/2000
				AP	200102041	D	00/00/0000
				AT	250036	T	15/10/2003
				AU	751103	B	08/08/2002
				AU	4950499	A	07/02/2000
				BR	9912109	A	02/05/2001
				CA	2336968	A	27/01/2000
				DE	69911415	D	00/00/0000
				DK	1095021	T	24/11/2003
				EE	200100010	A	17/06/2002
				EP	1095021	A,B	02/05/2001
				SE	1095021	T3	
				HR	20010039	A	31/12/2001
				HU	0103224	A	28/01/2002
				IL	140346	D	00/00/0000
				JP	2002520395	T	09/07/2002
				NO	20010211	A	15/03/2001
				NZ	508923	A	27/09/2002
				PL	345388	A	17/12/2001
				SE	9901270	D	00/00/0000
				ZA	200108265	A	08/01/2003
				SE	0000663	A	26/10/2001

US 2001/0003121 A 07/06/2001 NONE

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE 2004/000227

US	6201024	B1	13/03/2001	AT	224360	T	15/10/2002
				AU	744280	B	21/02/2002
				AU	1791399	A	28/06/1999
				BR	9813390	A	03/10/2000
				CA	2312420	A	17/06/1999
				CN	1284057	T	14/02/2001
				DE	69808130	D,T	28/05/2003
				DK	1036059	T	02/12/2002
				EE	200000378	A	17/12/2001
				EP	1036059	A,B	20/09/2000
				SE	1036059	T3	
				ES	2184352	T	01/04/2003
				HU	0004434	A-	28/05/2001
				ID	28003	A	00/00/0000
				IL	136369	D	00/00/0000
				JP	2001525392	T	11/12/2001
				NO	20002786	A	31/07/2000
				NZ	504447	A	26/04/2002
				PL	340906	A	12/03/2001
				PT	1036059	T	28/02/2003
				SE	9704544	D	00/00/0000
				SI	1036059	T	00/00/0000
				SK	8432000	A	11/12/2000
				TR	200001605	T	00/00/0000
				US	6258838	B	10/07/2001
				US	6303659	B	16/10/2001
				US	2001003121	A	07/06/2001
				WO	9929661	A	17/06/1999
				EP	0965900	A	22/12/1999
				SE	510648	C	14/06/1999
				SE	9802188	A	14/06/1999
				US	6213363	B	10/04/2001

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE 2004/000227

US	6242470	B1	05/06/2001	AT	234274	T	15/03/2003
				AU	746716	B	02/05/2002
				AU	1791499	A	28/06/1999
				BR	9813368	A	03/10/2000
				CA	2312889	A	17/06/1999
				CN	1280560	T	17/01/2001
				DE	69812159	D,T	18/12/2003
				DK	1036058	T	30/06/2003
				EE	200000320	A	15/08/2001
				EP	1036058	A,B	20/09/2000
				SE	1036058	T3	
				ES	2195433	T	01/12/2003
				HK	1028594	A	00/00/0000
				HU	0100431	A	30/07/2001
				IL	136503	D	00/00/0000
				JP	2001525391	T	11/12/2001
				NO	20002785	A	01/08/2000
				NZ	504375	A	29/08/2003
				PL	340890	A	12/03/2001
				PT	1036058	T	31/07/2003
				RU	2197477	C	27/01/2003
				SE	9704545	D	00/00/0000
				SK	8412000	A	07/11/2000
				TR	200001558	T	00/00/0000
				WO	9929660	A	17/06/1999
				SE	9802189	D	00/00/0000

US	2002/0193414	A	19/12/2002	NONE		
----	--------------	---	------------	------	--	--

WO	03041707	A1	22/05/2003	SE	0103836	D	00/00/0000
----	----------	----	------------	----	---------	---	------------

US	2003/0144293	A	31/07/2003	NONE		
----	--------------	---	------------	------	--	--

EP	1310493	A1	14/05/2003	BR	0204588	A	16/09/2003
				CA	2411544	A	12/05/2003
				JP	2003183263	A	03/07/2003
				US	2003144293	A	31/07/2003
				WO	03042190	A	22/05/2003